Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma (Q43752059)

26 November 2017

Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma (English)

1 reference

26 November 2017

Atsuko Katagiri

1

1 reference

26 November 2017

Kentaro Nakayama

2

1 reference

26 November 2017

Mohammed Tanjimur Rahman

3

1 reference

26 November 2017

Munmun Rahman

4

1 reference

26 November 2017

Hiroshi Katagiri

5

1 reference

26 November 2017

Naomi Nakayama

6

1 reference

26 November 2017

Masako Ishikawa

7

1 reference

26 November 2017

Tomoka Ishibashi

8

1 reference

26 November 2017

Kouji Iida

9

1 reference

26 November 2017

Hiroshi Kobayashi

10

1 reference

26 November 2017

Yoshiro Otsuki

11

1 reference

26 November 2017

Satoru Nakayama

12

1 reference

26 November 2017

Kohji Miyazaki

13

1 reference

26 November 2017

18 November 2011

1 reference

26 November 2017

1 reference

26 November 2017

25

1 reference

26 November 2017

2

1 reference

26 November 2017

282-288

1 reference

https://scigraph.springernature.com/pub.10.1038/modpathol.2011.161

26 November 2017

0 references

cites work

Cancer statistics, 1995.

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Phase III randomized trial of 12 versus 3 months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a Southwest Oncology Group and Gynecologic Oncology Group tria

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Clear cell carcinoma of the ovary: a retrospective multicentre experience of 254 patients with complete surgical staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

The role of hepatocyte nuclear factor-1beta in the pathogenesis of clear cell carcinoma of the ovary

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Cystic and adenofibromatous clear cell carcinomas of the ovary: distinctive tumors that differ in their pathogenesis and behavior: a clinicopathologic analysis of 122 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

DNA copy numbers profiles in affinity-purified ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Purification and characterization of mSin3A-containing Brg1 and hBrm chromatin remodeling complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Diversity and specialization of mammalian SWI/SNF complexes

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

The SWI/SNF complex and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Genomic and functional evidence for an ARID1A tumor suppressor role

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

ARID1A mutations in endometriosis-associated ovarian carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Clinicopathological significance of loss of ARID1A immunoreactivity in ovarian clear cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Molecular pathogenesis of ovarian borderline tumors: new insights and old challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Secondary cytoreduction for patients with recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

The role of surgery in ovarian cancer with special emphasis on cytoreductive surgery for recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

Ovarian atypical endometriosis: its close association with malignant epithelial tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

7 January 2021

IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis in ovarian carcinoma of clear cell subtype

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

7 January 2021

Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

7 January 2021

Secondary cytoreductive surgery for patients with relapsed epithelial ovarian carcinoma: who benefits?

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

7 January 2021

Clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy in stage III disease

1 reference

https://api.crossref.org/works/10.1038%2FMODPATHOL.2011.161

7 January 2021

10.1038/MODPATHOL.2011.161

Identifiers

DOI

1 reference

Dimensions Publication ID

26 November 2017

0 references

1 reference